Source comparison
CJC-1295 vs IGF-1 LR3 — Research Peptide Comparison
Research published in the Journal of Clinical Endocrinology & Metabolism found that growth hormone secretagogues and direct IGF-1 analogs produce distinct metabolic and anabolic outcomes despite both targeting growth pathways. The difference isn't subtle. CJC
This comparison does not assign a generated winner or score.
- Research published in the Journal of Clinical Endocrinology & Metabolism found that growth hormone secretagogues and direct IGF-1 analogs produce distinct metabolic and anabolic outcomes despite both targeting growth pathways. The difference isn't subtle. CJC-1295 amplifies endogenous pulsatile growth hormone (GH) secretion through GHRH receptor activation, while IGF-1 LR3 (Long R3 Insulin-like Growth Factor-1) bypasses the GH axis entirely and binds directly to IGF-1 receptors in target tissues. One modulates upstream signaling; the other delivers downstream effects without pituitary involvement.
- We've supplied both peptides to research labs investigating metabolic regulation, muscle protein synthesis, and tissue repair mechanisms. The choice between CJC-1295 and IGF-1 LR3 isn't about potency. It's about which biological pathway your study design requires.
- What is the difference between CJC-1295 and IGF-1 LR3?
- CJC-1295 is a growth hormone-releasing hormone (GHRH) analog that extends endogenous GH pulse amplitude and duration by binding to pituitary GHRH receptors with a plasma half-life of approximately 6–8 days. IGF-1 LR3 is a synthetic analog of insulin-like growth factor 1 with an arginine substitution at position 3 and a 13-amino-acid N-terminal extension, resulting in reduced binding to IGF-binding proteins (IGFBPs) and a half-life of 20–30 hours. Significantly longer than native IGF-1's 10-minute circulation time. CJC-1295 works through the hypothalamic-pituitary axis; IGF-1 LR3 acts peripherally at the receptor level.
- Yes, CJC-1295 and IGF-1 LR3 target growth pathways. But through entirely separate mechanisms that produce different systemic effects. CJC-1295 preserves the body's natural feedback loops because it amplifies existing GH pulses rather than replacing them, making it suitable for research models examining physiological GH patterns. IGF-1 LR3 bypasses GH entirely, delivering localized anabolic signaling without triggering upstream hormone cascades. Ideal for tissue-specific studies where isolated IGF receptor activation is the variable of interest. This article covers the distinct receptor mechanisms of CJC-1295 vs IGF-1 LR3, their differing half-lives and dosing protocols in research settings, and how each peptide's structure determines its biological behavior.